Tango Therapeutics TNGX Collaboration Revenue — Contract With Customer Liability Revenue Recognized
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityRevenueRecognized.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized?
- Tango Therapeutics (TNGX) reported collaboration revenue — contract with customer liability revenue recognized of $0 in Q1 2026.
- How has Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized changed year-over-year?
- Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized decreased by 100.0% year-over-year, from $5.4M to $0.
- What is the long-term trend for Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized?
- Over 4 years (2021 to 2025), Tango Therapeutics's collaboration revenue — contract with customer liability revenue recognized has grown at a 24.5% compound annual growth rate (CAGR), from $26M to $62.4M.
- What does collaboration revenue — contract with customer liability revenue recognized mean?
- This metric represents the portion of deferred revenue recognized during the period resulting from the satisfaction of performance obligations under collaborative research and development agreements. It reflects the conversion of upfront payments or milestone-related liabilities into recognized revenue as the company fulfills its contractual obligations to partners. This measure is critical for assessing the pace at which the company achieves technical or clinical milestones within its strategic partnerships.